Stock PSTX POSEIDA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Real-time Estimate Cboe BZX
Other stock markets
 18:27:37 27/06/2024 BST 		5-day change 1st Jan Change
2.66 USD +7.69% Intraday chart for Poseida Therapeutics, Inc. -1.32% -22.17%
05-14 Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises MT
05-14 Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises
Poseida Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos
Poseida Therapeutics, Inc. and Xyphos Biosciences, Inc. Enter into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Poseida Therapeutics, Inc. Announces Executive Changes
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Poseida Therapeutics Reports Positive Results of Phase 1 Blood Cancer Treatment Trial
Poseida Therapeutics, Inc. Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology Annual Meeting
Poseida Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Poseida Therapeutics, Inc. Announces Board Changes
Poseida Therapeutics, Inc. Announces Chief Executive Officer Changes
Poseida Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Poseida Therapeutics Secures $50 Million Strategic Investment From Astellas; Shares Gain
Poseida Therapeutics Says US FDA Clears Investigational New Drug Application for B-cell Malignancies Treatment Candidate
Poseida Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Poseida Therapeutics, Inc. Appoints Kristin Yarema as President, Cell Therapy
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PSTX Stock
  4. News Poseida Therapeutics, Inc.
  5. Other languages